Pulmonary Arterial Hypertension Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

Posted on
by

Pulmonary Arterial Hypertension Pipeline Analysis (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 55+ key pharma and biotech companies are working on 55+ pipeline drugs in the Pulmonary Arterial Hypertension therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

“Pulmonary Arterial Hypertension Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Pulmonary Arterial Hypertension Market. 

The Pulmonary Arterial Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Pulmonary Arterial Hypertension Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Pulmonary Arterial Hypertension and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Pulmonary Arterial Hypertension market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, featured press releases from company/university websites, industry-specific third-party sources, etc.  

Pulmonary Arterial Hypertension Pipeline Analysis

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Pulmonary Arterial Hypertension Therapeutic Segment @

https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

Pulmonary Arterial Hypertension Therapeutics Landscape

There are approx. 55+ key companies developing therapies for Pulmonary Arterial Hypertension. Currently, Liquidia Technologies is leading the therapeutics market with its Pulmonary Arterial Hypertension drug candidates in the most advanced stage of clinical development.

The Leading Players in the Pulmonary Arterial Hypertension Therapeutics Market Include:

  • Merck Sharp & Dohme

  • Acceleron Pharma

  • Liquidia Technologies

  • Gossamer Bio

  • Resverlogix

  • PhaseBio Pharmaceuticals

  • Pharmosa BioPharm

  • Complexa

  • Gmax Biopharm Australia

  • Mezzion

  • Radikal Therapeutics

  • Galectin Therapeutics

  • Altavant Sciences

  • Ribomic

And Many Others

Pulmonary Arterial Hypertension Emerging and Marketed Drugs Covered in the Report Include:

  • Aurora-GT: United Therapeutics Corporation

  • L606: Pharmaosa Biopharma Inc.

  • LIQ861: Liquidia Technologies

  • Macitentan: Actelion Pharmaceuticals

  • MK5475: Merck Sharp & Dohme Corp.

  • Ralinepag: Arena Pharmaceuticals

  • RT234: Respira Therapeutics

  • Sildenafil (Revatio): Pfizer

  • Sotatercept: Acceleron Pharma

  • Treprostinil Palmitil: Insmed Incorporated

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Pulmonary Arterial Hypertension Current Treatment Patterns

4. Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Pulmonary Arterial Hypertension Late Stage Products (Phase-III)

7. Pulmonary Arterial Hypertension Mid-Stage Products (Phase-II)

8. Pulmonary Arterial Hypertension Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pulmonary Arterial Hypertension Discontinued Products

13. Pulmonary Arterial Hypertension Product Profiles

14. Key Companies in the Pulmonary Arterial Hypertension Market

15. Key Products in the Pulmonary Arterial Hypertension Therapeutics Segment

16. Dormant and Discontinued Products

17. Pulmonary Arterial Hypertension Unmet Needs

18. Pulmonary Arterial Hypertension Future Perspectives

19. Pulmonary Arterial Hypertension Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

Schistosomiasis Market

“Schistosomiasis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Schistosomiasis market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Schistosomiasis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/